Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia
Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure
NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults
Evidence-based recommendations on lanadelumab (Takhzyro) for preventing recurrent attacks of hereditary angioedema in people aged 12 and over
NICE is unable to make a recommendation about the use in the NHS of ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults
NICE is unable to make a recommendation about the use in the NHS of ramucirumab (Cyramza) for treating unresectable hepatocellular carcinoma after sorafenib
Evidence-based recommendations on capecitabine for treating metastatic colorectal cancer in adults
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults
NICE is unable to make a recommendation on recombinant human parathyroid hormone for treating hypoparathyroidism because Shire Pharmaceuticals
Evidence-based recommendations on avatrombopag (Doptelet) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults
NICE is unable to make a recommendation about the use in the NHS of bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults
NICE is unable to make a recommendation about the use in the NHS of pomalidomide (Imnovid) with bortezomib and dexamethasone for relapsed or refractory myeloma
NICE is unable to make a recommendation about the use in the NHS of lenalidomide (Revlimid) with bortezomib and dexamethasone for untreated multiple myeloma
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema
Evidence-based recommendations on apixaban (Eliquis) for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation (AF)
Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...
Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia (CLL) in adults
NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for untreated..
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C
Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults
Evidence-based recommendations on immunosuppressive therapy for kidney transplant in children and young people
Evidence-based recommendations on immunosuppressive therapies for preventing kidney rejection in adults
Evidence-based recommendations on tofacitinib (Xeljanz) for treating moderate to severe rheumatoid arthritis (rheumatism) in adults
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults
Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee
Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults
Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults
Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults
NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence
NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults
Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults